Infectious Disease Pathways

17 pathways

Work through 17 interactive infectious disease decision pathways — branching, guideline-grounded workflows that take you from presentation to assessment, risk stratification and management. Each pathway cites its source (NICE, ESC, AHA and specialty guidance), embeds the relevant calculators, and makes escalation and safety-netting explicit. For decision support only — apply clinical judgement and local protocols.

HIV Diagnosis and Initial Management

HIV testing, CD4/viral load interpretation, and ART initiation

BHIVA 2023 / NICE
Cellulitis Management

Eron class severity assessment, antibiotic selection, and admission criteria for cellulitis

CREST 2005 / BSAC
Tuberculosis Diagnosis and Treatment

TB investigation, LTBI testing, and treatment regimens — standard and drug-resistant

NICE NG33 2016
UTI Management

Uncomplicated UTI, catheter-associated UTI, and upper UTI management

NICE NG109 2018
COVID-19 Management

COVID-19 severity assessment, escalation, and antiviral/steroid treatment

NICE CG247 / WHO 2023
Infective Endocarditis — Antibiotic Therapy

Empirical and organism-directed antibiotic regimens for infective endocarditis

ESC 2023 / BCS / BHIVA
Returning Traveller — Fever

Travel history + targeted workup, malaria first, isolation for VHF risk, notification of NaTHNaC / Public Health.

NaTHNaC; PHE; ESCMID 2018
Malaria — Diagnosis & Management

Thick + thin film + RDT, distinguish severe (artesunate) from uncomplicated (ACT), species-specific therapy, severe complications.

PHE 2016; WHO 2023
Hepatitis B / C — Screening & Management

Risk-based screening, distinguish acute / chronic, antiviral therapy, HCC surveillance.

BASL 2024; EASL; NICE NG161
Lyme Disease

NICE NG95 — erythema migrans = clinical diagnosis; targeted serology for non-EM features; doxycycline first-line.

NICE NG95 (2018)
Catheter-Associated Bloodstream Infection / Line Sepsis

Recognise CRBSI, paired peripheral + line cultures, line removal threshold, antimicrobial choice by organism.

IDSA 2009; ESCMID 2018
Recurrent UTI in Women

≥2 UTI in 6 months / ≥3 in 12 months — investigation + non-antibiotic + antibiotic prevention strategies.

NICE NG112 / CKS; EAU 2024
STI Screen / Management

BASHH — comprehensive screen for chlamydia, gonorrhoea, syphilis, HIV, hepatitis B/C; partner notification.

BASHH 2024
Pyrexia of Unknown Origin (PUO) Workup

Definition (Petersdorf), structured stepwise workup (history, exam, bloods, imaging, biopsy), MDT.

Petersdorf 1961 (modified); ESCMID
Diabetic Foot Infection

IDSA / IWGDF — severity classification, multidisciplinary foot team, antibiotic + surgical, osteomyelitis recognition.

IWGDF 2023; NICE NG19
Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila)

Clinical features + targeted testing, macrolide / tetracycline / fluoroquinolone, public health (Legionella).

BTS 2023; IDSA
Syphilis Diagnosis & Management

Stage clinically + serologically, benzathine penicillin G, Jarisch-Herxheimer counselling, partner notification, follow-up.

BASHH 2024